Cytek Biosciences, Inc. (CTKB) Form 10-Q — Aug 5, 2026
Cytek Biosciences reported second-quarter 2026 revenue of $48.1 million, up 6% from $45.6 million a year earlier, with six-month revenue of $92.3 million also up 6%. Service revenue grew fastest at 10% for the quarter as the installed instrument base expanded. Net loss more than doubled to $12.2 million, or $0.09 per share, from $5.6 million in Q2 2025, driven by a 24% jump in general and administrative expense tied to litigation-related costs and severance, plus a $1.6 million impairment that wrote a non-marketable equity investment down to zero.
Key figures
- Revenue
- 48140000
- Total Debt
- 246000
- Revenue Yoy
- 6%
- Total Assets
- 446934000
- Cash Position
- 73846000
- Shares Outstanding
- 129983253
- Six month revenue
- 92275000
- Ga expense q2 2026
- 16825000
- Gross margin q2 2025
- 52%
- Gross margin q2 2026
- 59%
- Ga expense yoy change
- +24%
- Legal settlement liability
- 8700000
- Tariff refund cogs benefit
- 2800000
- Stock based comp six months
- 10200000
- Equity investment impairment
- 1600000
- Cash and marketable securities
- 262000000
- Gross margin q2 2026 ex tariff refund
- 53%
Price after filing
Close on the filing date to close N calendar days later (from $4.28). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.